Please assess the completion status of the following clinical trial:

Trial Title: Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients must meet the following criteria within 28 days of randomization (unless otherwise indicated) to be enrolled in the protocol:~* Histologically or cytologically proven adenocarcinoma of the pancreas. If the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled.~* Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)~* The tumor must be deemed as being borderline resectable. Final CT confirmation of surgical staging/ eligibility will be at the discretion of the pancreatic surgeon of the patient.~* Disease is confined to locoregional site as confirmed by the CT and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits. Diagnostic laproscopy will be only if absolutely required~* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT~* Screening Endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be used.~* Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-2.~* Age \> 18~* Estimated life expectance \> 12 weeks~* If female patient is of child bearing potential, she must have a negative serum pregnancy test (βhCG) documented up to 72hrs prior to administration of first study drug~* Patient has screening blood work performed which includes the following (should be drawn ≤ 14 days prior to randomization)~* absolute neutrophil count (ANC) \> 1.5 x 109/L~* Platelet count ≥ 100000/mm3~* Hemoglobin (HgB) ≥ 9g/dL~* aspartate aminotransferase (AST),Alanine Aminotransferase (ALT)≤ 2.5 x upper limit of normal (ULN) Total Bilirubin ≤ ULN~* Serum Cr within normal limits (WNL)~* Coagulation studies with Prothrombin Time and International Normalized Ratio (PT/INR) and partial thromboplastin time (PTT) within normal limits (±15%). • Patient has a urinalysis obtained (≤14 days prior to randomization) and the results are deemed not clinically significant by the investigator.~* Patient has no evidence of jaundice at the time of enrolment. If stent is required to alleviate jaundice, it should be metallic. If patient has a previously placed stent and this is plastic, this should be changed to metallic.~* Patient's pain symptoms have remained stable with no adjustment to analgesics within 7 days prior to randomization. Patient must be able to swallow entreat medications with no requirement for a feeding tube. Patient's must not have intractable nausea or vomiting which prohibits the patient from oral medications~* Diabetes must be controlled prior to enrollment~* Disease must be encompassed in a reasonable SBRT portal as defined by the treating radiation oncologist~Exclusion Criteria:~* Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas~* Evidence of distant metastasis on upright chest x-ray, CT or other staging studies~* Subjects with recurrent disease~* Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment~* Prior chemotherapy~* Subjects in their reproductive age who are breast feeding or have a positive pregnancy test~* Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician~* Concurrent active infection~* Previous or current malignancies of other histologies within the last 3 yrs prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer~* Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C~* Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization.~* Patient who has a history of allergy or hypersensitivity to any of the study drugs.~* Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies~* Patients with greater than 2 screening peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine/nab-paclitaxel (Type: EXPERIMENTAL): three cycles of treatment in the gemcitabine/nab-paclitaxel
- mFOLFIRINOX (Type: EXPERIMENTAL): 6 cycles in the mFOLFIRINOX

Based on this trial design, predict the completion outcome and termination type (if applicable).